An electrochemiluminescence immunoassay, often abbreviated ECLIA or sometimes ECLIA, is a laboratory test that detects and measures specific proteins, hormones, or antibodies in a sample by combining two technologies: immunoassay (which uses antibodies to find a target molecule) and electrochemiluminescence (which generates light through an electrical reaction to measure how much of that target is present). The technique has become a workhorse in clinical laboratories worldwide, particularly for hormone testing, cardiac biomarkers, and infectious disease screening, because it offers a combination of sensitivity and speed that older methods struggle to match.
How Light Gets Made at an Electrode
Electrochemiluminescence, or ECL, is the generation of light triggered by an electrical signal at an electrode surface. When voltage is applied, a chemical reaction takes place that pushes a special light-emitting molecule into an excited energy state, and as that molecule relaxes back to its ground state, it releases a photon.1Accounts of Chemical Research. Light Conversion by Electrochemiluminescence at Semiconductor Surfaces The most common light-emitting molecule used in commercial ECLIA systems is a ruthenium-based compound, tris(bipyridine)ruthenium(II), paired with a chemical partner called a coreactant that helps the reaction along. The traditional coreactant is tri-n-propylamine, or TPrA.
What makes this approach powerful for diagnostics is the on/off switch that voltage provides. No light is produced until the instrument deliberately triggers the reaction, which means background glow from the sample itself is essentially zero. That low background is a big part of why ECLIA can detect vanishingly small quantities of a target molecule.
From Light to Measurement
The “immunoassay” half of the name refers to how the test finds its target. Antibodies designed to recognize a specific molecule (say, a thyroid hormone or a cardiac protein) are attached to tiny magnetic beads. When a patient’s blood sample is mixed with these beads, the antibodies grab onto whatever target molecules are present. A second antibody, labeled with the ruthenium light-emitting tag, then binds to the captured target, forming a sandwich structure: bead–antibody–target–labeled antibody.
A magnet pulls the bead complexes to the electrode surface, washing away everything else in the sample. Voltage is applied, the ruthenium tag lights up, and a photomultiplier measures how much light is produced. More target molecules in the sample means more labeled antibodies captured, which means a brighter signal. The instrument translates that brightness into a concentration.
This sandwich format is the most common arrangement, but competitive formats also exist. In a competitive assay, the target molecule in the patient’s sample competes with a labeled version of the same molecule for a limited number of antibody binding sites. The more target present, the less labeled molecule gets captured, so the signal actually goes down as concentration rises. These two formats matter when it comes to understanding certain kinds of interference, as we will see later.
Where ECLIA Shows Up in Routine Medicine
If you have had blood drawn for a thyroid panel, a cardiac troponin test in an emergency room, or a hepatitis screening, there is a good chance the lab ran an ECLIA. The technology sits inside large automated analyzers made by companies like Roche (the cobas and Elecsys platforms are probably the most widely installed), and these machines handle thousands of samples a day with minimal human intervention.
Thyroid Hormones
Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) are among the most frequently ordered blood tests in medicine, and ECLIA platforms handle them with strong precision. In performance testing on the Roche Elecsys system, the variation between repeated measurements of the same sample was less than about 2.3% for TSH and FT4, meaning the instrument gives nearly the same answer each time it measures the same specimen.2PubMed Central. Performance characteristics of three automated immunoassays for thyroid hormones That kind of reproducibility matters when clinicians are tracking small shifts in a patient’s hormone levels over months or years to adjust medication doses.
Cardiac Troponin
One of the most consequential clinical applications has been the high-sensitivity cardiac troponin T (hs-cTnT) assay, which runs on an ECLIA platform. Troponin is a protein released when heart muscle cells are damaged, and measuring tiny amounts of it helps emergency departments diagnose or rule out heart attacks. The high-sensitivity version of this test improves diagnostic accuracy in patients with suspected heart attacks, and a negative result carries strong reassurance that a heart attack has not occurred.3PubMed Central. High-sensitive cardiac troponin T That sensitivity gain is especially valuable for patients who arrive soon after symptoms begin, when troponin levels may still be rising from barely detectable amounts.
In a large trial involving over 31,000 patients with troponin levels below the alarm threshold on arrival, using the high-sensitivity ECLIA assay to rule out heart attack early reduced the average length of stay from roughly ten hours to about seven hours, and the proportion of patients safely discharged from the emergency department rose from 50% to 71%.4PubMed Central. High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial That is a meaningful change in how emergency departments function and how quickly low-risk patients get home.
The flip side of greater sensitivity is that the test also picks up heart muscle damage from causes other than a classic heart attack, such as heart failure, kidney disease, or severe infections. After one hospital system adopted the high-sensitivity troponin assay, diagnoses of type 2 heart injury (damage not caused by a blocked artery) rose by about 22%, and chronic heart injury diagnoses rose by roughly 43%.5PubMed Central. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction Extra sensitivity is only helpful when clinicians know what to do with those additional findings, and that remains a work in progress.
Infectious Disease Screening
ECLIA platforms are also used for screening blood for antibodies to hepatitis C, HIV, hepatitis B, and other pathogens. These assays offer improved precision, faster turnaround, and higher throughput compared to earlier generation tests.6Diagnostic Microbiology and Infectious Disease. Comparison of 2 different antibody assay methods, Elecsys Anti-HCVII (Roche) and Vidas Anti-HCV (Biomerieux), for the detection of antibody to hepatitis C virus in Egypt In blood banks and high-volume screening programs, the combination of automation and sensitivity makes ECLIA a practical choice for processing large numbers of samples reliably.
How ECLIA Compares to ELISA
The test most people have heard of in this space is the enzyme-linked immunosorbent assay, or ELISA. Both ELISA and ECLIA use antibodies to capture a target, but they differ in how they generate and read the signal. ELISA relies on an enzyme reaction that produces a color change, measured by how much light a solution absorbs. ECLIA generates light directly, measured by a photon detector. That difference in detection physics gives ECLIA a wider useful measurement range and lower detection limits in many applications.
In a head-to-head study measuring antibody responses to malaria vaccine antigens, the ECLIA platform showed strong linearity across a 625-fold range of antibody concentrations, maintaining reliable readouts even at very low levels.7PubMed Central. Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination A wider linear range means fewer samples need to be diluted and re-run because they fell outside the measurable window, which saves time and reduces error.
A study comparing the two platforms for measuring a brain injury biomarker (Tau-A) in serum found that only about 1% of samples fell below the detection limit on the ECLIA platform, compared to roughly 11% on the ELISA.8PubMed. Quantification of Tau-A in serum after brain injury: a comparison of two analytical platforms, ELISA and electrochemiluminescence immunoassay The broader dynamic range of the ECLIA also allowed it to distinguish between patient groups, like separating mild strokes from severe ones, that the ELISA could not reliably tell apart. For research and clinical purposes, being able to detect and differentiate at low concentrations opens up possibilities that a less sensitive platform simply cannot reach.
None of this means ELISA is obsolete. It remains cheaper per test, simpler to set up, and perfectly adequate for many applications. But when sensitivity, throughput, and dynamic range matter, ECLIA has a genuine edge.
The Biotin Problem
One well-documented vulnerability of ECLIA systems is interference from biotin, also known as vitamin B7. Many ECLIA assays use biotin-streptavidin chemistry as a molecular glue to attach antibodies to the magnetic beads. When a patient has high biotin levels in their blood, that free biotin competes with the assay’s own biotin-labeled components for binding sites, and the result gets skewed.
The direction of the error depends on the assay format. In sandwich immunoassays (the kind used for most large proteins and hormones like TSH and troponin), biotin interference tends to push measured values falsely low, because the free biotin prevents the labeled antibody from being properly captured at the electrode. In competitive immunoassays (used for some small molecules and steroid hormones), the effect is reversed: results go falsely high. One study evaluating biotin interference across a panel of ECLIA tests found that concentrations were spuriously decreased in twelve sandwich assays and falsely increased in eleven competitive assays.9Anales de la Real Academia Nacional de Farmacia. Biotin interference in several electrochemiluminescence immunoassays (eclia)
Who is at risk? Most people eating a normal diet have biotin levels too low to cause problems. But patients taking high-dose biotin supplements, which have been marketed for hair and nail health and investigated at very high doses for multiple sclerosis, can reach concentrations that affect results. Some laboratories now routinely flag samples or add biotin-blocking agents to counteract this. If you take biotin supplements and have blood work coming up, it is worth mentioning to your doctor. Newer assay formulations from manufacturers have also begun addressing this vulnerability with modified chemistries that are less susceptible to biotin interference.
Assay Sensitivity to Sample Conditions
Beyond biotin, any immunoassay can be affected by what is in the sample alongside the target molecule. Hemolysis (broken red blood cells), lipemia (excess fats making the sample milky), and high bilirubin can all potentially interfere. One advantage of the ECLIA workflow is that the magnetic bead capture and washing step physically separates the target-antibody complex from most of the sample matrix before the light-generating step happens. This built-in cleanup reduces, though does not eliminate, matrix effects.
In preclinical validation work for a recombinant protein assay on an ECLIA platform, the assay was shown to be insensitive to matrix effects up to the addition of 7% of the total reaction volume from serum, with accuracy and precision staying within about 15% across the measurement range.10Journal of Pharmaceutical and Biomedical Analysis. Development of an equilibrium immunoassay using electrochemiluminescent detection for a novel recombinant protein product and its application to pre-clinical product development For most routine clinical samples, this tolerance is more than sufficient, but unusual samples (severely hemolyzed specimens or samples from patients on certain therapies) still warrant caution.
Beyond the Hospital Lab
While clinical diagnostics represent the biggest commercial market for ECLIA, the underlying technology has found its way into other fields. Food safety is one notable area. Detecting trace levels of mycotoxins, the toxic compounds produced by molds in grains, nuts, and other crops, requires extreme sensitivity because regulatory limits are set at very low concentrations. Researchers have built ECLIA-based sensors specifically for this purpose, using metal-organic frameworks and other advanced materials to push detection limits even lower.11PubMed Central. Application of Metal-Organic Framework-Based Electrochemiluminescence Sensors for Mycotoxin Detection in Food
One example is a sensor designed to detect ochratoxin A, a mycotoxin that can contaminate cereals and wine. By using a quench-type ECL immunosensor with specially engineered nanoparticles, researchers achieved a detection limit of 4.8 femtograms per milliliter, an extraordinarily tiny concentration, and demonstrated acceptable recovery rates when testing spiked food samples.12PubMed. Polydopamine@ZIFs with enhanced electrochemiluminescence quenching performance for mycotoxin detection These are still largely research-stage tools rather than routine commercial instruments, but they illustrate how far the platform’s sensitivity can be pushed.
Measuring More Than One Thing at Once
A frontier in ECLIA development is multiplexing: measuring several different targets from a single sample in a single run. In standard ECLIA, one measurement channel detects one analyte. Multiplex approaches aim to use different light-emitting tags that can be distinguished by the voltage needed to trigger them or by the color of light they produce.
The potential-resolved strategy, where different luminophores emit at different applied voltages, has attracted particular interest because it does not require complex optical equipment to separate signals. It just requires applying voltage in steps and reading the light at each step.13PubMed Central. Recent advances and future prospects of the potential-resolved strategy in ratiometric, multiplex, and multicolor electrochemiluminescence analysis Researchers have demonstrated this concept for simultaneous detection of two cancer biomarkers, carbohydrate antigen 125 and carbohydrate antigen 19-9, in a single assay with detection limits in the range of 0.03 to 0.08 mU per milliliter.14PubMed. Potential-resolved electrochemiluminescence multiplex immunoassays with isolated cathodic and anodic co-reactants and pre-oxidized Ag-doping methionine-stabilized Au nanoclusters
Spatially resolved approaches are another route to multiplexing: instead of separating signals by voltage, different capture antibodies are printed in distinct spots on the electrode surface, and an imaging system reads which spots light up and how brightly. A recent study using a spatially resolved ECLIA for two brain and heart injury markers showed that adding an iridium-based signal amplifier produced a roughly six-fold increase in signal brightness and a five-fold improvement in analytical sensitivity.15ACS Sensors. Redox-Mediated Signal Enhancement of a Spatially Resolved Electrochemiluminescence Immunoassay If these approaches mature, a single emergency department blood draw could simultaneously screen for heart attack, stroke, and traumatic brain injury biomarkers from one tube.
New Chemistry Under Development
The classic ruthenium-based system has served well for decades, but researchers are exploring alternative light-emitting materials that could broaden what ECLIA can do. Semiconductor quantum dots, tiny crystals whose light-emission properties can be tuned by adjusting their size, offer advantages in brightness and the ability to produce light at different wavelengths.16PubMed Central. Electrochemiluminescence of Semiconductor Quantum Dots and Its Biosensing Applications: A Comprehensive Review That tunability is particularly useful for multiplexing, where you want different tags emitting distinguishable colors.
Iridium-based complexes are another area of active work. One study synthesized nanowires from an iridium complex linked to nitrogen-doped carbon quantum dots and achieved a five-fold increase in light output compared to the iridium complex alone.17PubMed Central. Facial Preparation of Cyclometalated Iridium (III) Nanowires as Highly Efficient Electrochemiluminescence Luminophores for Biosensing Brighter tags mean better sensitivity, particularly for targets present at extremely low concentrations.
Even the coreactant, the chemical partner that helps drive the light-producing reaction, is being rethought. The traditional coreactant, TPrA, does not dissolve well in water and degrades easily, which limits its performance in biological samples. A recently reported alternative, 4-(dimethylamino)pyridine or 4-DMAP, is highly water-soluble and chemically stable under normal conditions. In testing with the standard ruthenium emitter, 4-DMAP generated signals more than 180 times higher than TPrA.18Cell Reports Physical Science. Discovery of a new coreactant for highly efficient and reliable electrochemiluminescence If that kind of improvement translates into commercial assays, detection limits could drop by orders of magnitude, opening ECLIA to analytes that are currently too scarce to measure reliably.
Engineering the Hardware
Improvements to ECLIA are not purely about chemistry. How the magnetic beads distribute across the electrode surface affects how evenly light is generated, and uneven bead coverage introduces noise into the measurement. Recent work on optimizing the flow rate at which beads are delivered to the electrode found that tuning it to roughly 18.5 microliters per second improved bead distribution uniformity and increased luminescence intensity by about 26% without any changes to the assay chemistry itself. The optimized system showed a linear response for TSH across a very wide concentration range and matched a commercial Roche analyzer with near-perfect agreement.19PubMed Central. An Enhanced Electrochemiluminescence Immunoassay Platform via Optimized Magnetic Bead Uniformity for Reliable Thyroid-Stimulating Hormone Monitoring This sort of engineering refinement is how incremental gains in precision accumulate over instrument generations.
ECL-based sensing systems have been widely adopted for detecting disease-related biomarkers in part because of practical engineering advantages: the electrical trigger provides precise timing and spatial control of when and where light appears, the magnetic separation step keeps backgrounds clean, and the entire process lends itself well to full automation.20PubMed Central. Electrochemiluminescence Systems for the Detection of Biomarkers: Strategical and Technological Advances These features have kept ECLIA competitive even as newer sensing technologies emerge, and they suggest the platform has considerable room to grow as new chemistries and multiplexing strategies move from research labs into routine use.